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Objectives: Evaluation of the impact of the implementation of practice guidelines, with or without their
reinforcement by a pharmacist, on the intra-hospital use of antibiotics.
Materials and methods: The duration of antibiotic treatment, their cost, and the length of patient stay
were compared in three secondary-care hospitals, before and after interventions that were designed to
promote rational antibiotic use. After randomization, hospital A received no intervention (control), local
practice guidelines were implemented in hospital B (low grade intervention), and these guidelines were
reinforced by a clinical pharmacist in hospital C (high grade intervention). Adherence to the guidelines
was measured in hospitals B and C. Multivariable statistical analyses were carried out to adjust for
confounding factors.
Results: None of the outcomes measured in the 1200 included patients decreased between the two
study periods in any hospital. Hospital A was significantly and independently associated with an
increase in the duration of antibiotic treatments, the cost of antibiotics (acquisition and global costs),
and the length of stay. Although these differences were not statistically significant, increases in hospi-
tal B were higher than in hospital C. Adherence to guidelines was significantly higher in hospital C.
Conclusions: Even though interdisciplinary interventions aiming at rationalizing antibiotic use could
not diminish the duration of treatments, their costs or the length of stay, they proved useful to control
the progression of these parameters.
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Introduction
Antibiotics represent approximately 30% of acute care hospi-
tals’ drug expenditures; they are prescribed for 20–50% of
inpatients, and contribute to the emergence of resistant micro-
organisms. Surveys have shown that 22–65% of antibiotic
prescriptions are either inappropriate or incorrect.1 Indeed,
several organizations have written action plans to control the
costs of antibiotics and limit their selective pressure on resist-
ant microorganisms through surveillance and interventions
promoting their rational use. Every health care professional,
including pharmacists, may play an important role in these
efforts.2
Different interventions have been described to guide a more
appropriate and cost-effective use of antibiotics in hospitals:
some are restrictive (automatic stop orders, restricted antibiotic
list, mandatory approval by infectious diseases specialists).
Others focus on education (face-to-face discussion, conferences,
distribution of printed material, audit with feed-back), or are
based on tools to help physicians in their decision making (prac-
tice guidelines, computer programs). The importance of combin-
ing strategies to enhance the success of any intervention has
been emphasized.3 Clinical practice guidelines are used to pro-
mote the rational use of antibiotics. They need to be adequately
prepared, implemented and supported to have a positive impact.4
Several studies support the role of the clinical pharmacist as a
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drug therapy advisor in institutional settings,5 fewer demonstrate
his/her impact on quality or cost in the implementation of anti-
biotic guidelines.6
The aim of this controlled ‘before–after’ study was to evalu-
ate the impact of the implementation of local practice guidelines,
with and without their reinforcement by a clinical pharmacist,
on the intra-hospital use of antibiotics.
Materials and methods
Setting and study design
The general medical wards and intensive care units of three compar-
able secondary-care non-university affiliated public hospitals in
western Switzerland (100–120 acute-care beds each, 5000–6000
admissions per year each, and similar case-mix indexes) were stu-
died during two 6 month periods (November 2001 to April 2002
and November 2002 to April 2003). Over each period of time, the
first 200 patients admitted to these wards of each hospital were
enrolled into the study provided they received antibiotic therapy.
Hospitals were randomly assigned to no intervention (hospital A,
control), implementation of guidelines only (hospital B, low grade
intervention), or implementation of guidelines with their reinforce-
ment by a clinical pharmacist (hospital C, high grade intervention).
Local practice guidelines, based on published recommendations, a
common drug formulary, and regional antibiotic susceptibility
patterns, were developed and implemented in hospitals B and C
between the two study periods by infectious diseases physicians,
pharmacists, and the heads of internal medicine of these two hospi-
tals. In hospital C, a clinical pharmacist reviewed the medical charts
and participated in clinical rounds twice weekly during the interven-
tion period. She informed the physicians on any deviation from the
guidelines, necessity to adjust dosages, and possibilities to narrow
the spectrum of activity of antibiotics or to switch to oral therapy.
Data collection
Data were collected from the medical charts. The outcome variables
were the length of hospital stay, the duration of the antibiotic treat-
ment (distinguishing oral and intravenous administrations), and
costs expressed as the cost of the substances and the global cost of
treatment including substances, devices, and nursing time for the
administration of the treatment. The adherence to guidelines in the
second study period was evaluated, in hospitals B and C, by a
blinded investigator.
Other collected variables included the age, the gender, the Charl-
son comorbidity index, microbiological results, the antibiotics used,
their indication, dosage and route of administration.
Statistical analysis
Proportions and medians were compared between hospitals and
study periods in univariate analysis by using x2, Fisher’s exact,
Kruskal–Wallis or Mann–Whitney tests, as appropriate.
After exclusion of outliers based on the inspection of histograms
and clinical appraisal, multivariable models were developed to
obtain adjusted outcome comparisons between hospitals and study
Table 1. Patients’ characteristics in the intervention and control hospitals during the pre- and post-intervention periods
Characteristic Hospital A, control
Hospital B, low grade
intervention
Hospital C, high grade
intervention P valuea
Pre-intervention period n = 200 n = 200 n = 200
patients admitted,b n 850 685 746
median age, years (extremes) 72.1 (14–94) 76.6 (15–97) 69.4 (19–97) 0.078
males, n (%) 94 (47) 89 (44.5) 98 (49) 0.665
Charlson comorbidity index, n (%) 0.027
0 83 (41.5) 56 (28) 60 (30)
1–3 92 (46) 106 (53) 101 (50.5)
> 3 25 (12.5) 38 (19) 39 (19.5)
nosocomial infections,c n (%) 10 (5) 9 (4.5) 12 (6) 0.788
difficult-to-treat infections,d n (%) 20 (10) 22 (11) 20 (10) 0.931
difficult-to-treat pathogens,e n (%) 2 (1) 8 (4) 7 (3.5) 0.153
Post-intervention period n = 200 n = 200 n = 200
patients admitted,b n 746 616 850
median age, years (extremes) 73.7 (14–95) 71.7 (16–103) 74.0 (18–98) 0.428
males, n (%) 90 (45) 93 (46.5) 98 (49) 0.720
Charlson comorbidity index, n (%) 0.245
0 77 (38.5) 61 (30.5) 58 (29)
1–3 95 (47.5) 101 (50.5) 106 (53)
> 3 28 (14) 38 (19) 36 (18)
nosocomial infections,c n (%) 6 (3) 1 (0.5) 10 (5) 0.025
difficult-to-treat infections,d n (%) 14 (7) 16 (8) 24 (12) 0.181
difficult-to-treat pathogens,e n (%) 2 (1) 8 (4) 4 (2) 0.161
ax2, Fisher’s exact or Kruskal–Wallis test.
bNumber of admissions necessary to reach the 200 pre-planned patients with criteria for inclusion.
cDefined as infections occurring more than 48 h after admission and not in incubation at the time of admission.
dInfections involving the bone or joints, the central nervous system, the vascular system (e.g. endocarditis), associated with a bacteraemia, or occurring in a
neutropenic patient.
eAcinetobacter sp., Enterobacter sp., Pseudomonas sp., Serratia marcescens, methicillin-resistant Staphylococcus aureus (MRSA), and Stenotrophomonas
maltophilia.
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Table 2. Durations of treatment, costs, and length of stay in the intervention and control hospitals during the pre-intervention (PRE) and post-intervention (POST) periods
Hospital A, control Hospital B, low grade intervention Hospital C, high grade intervention
Outcomes PRE POST
TR or CRa
[95% CI] P value PRE POST
TR or CRa
[95% CI] P value PRE POST
TR or CRa
[95% CI] P value
Median duration
of iv antibiotics,
days (IQ range)b
2.0 (2.0) 2.5 (2.0) 1.11
[0.94–1.30]
0.230 5.0 (4.0) 5.0 (4.5) 1.10
[0.95–1.27]
0.203 4.0 (2.0) 4.0 (2.0) 1.05
[0.90–1.22]
0.533
Median duration
of all antibiotics,
days (IQ range)
6.0 (5.0) 8.0 (5.0) 1.18
[1.06–1.31]
0.002 8.0 (7.0) 8.0 (7.0) 1.08
[0.97–1.20]
0.183 7.0 (5.0) 7.0 (5.0) 1.02
[0.91–1.13]
0.753
Median cost of
antibiotics,c Euros
(IQ range)
27.5 (53.5) 37.4
(63.1)
1.35
[1.07–1.70]
0.011 68.4
(103.5)
82.3
(118.3)
1.22
[0.96–1.54]
0.099 45.9 (67.6) 46.0
(101.4)
1.11
[0.88–1.40]
0.391
Median global
cost,c,d Euros
(IQ range)
51.9 (84.5) 65.4
(85.3)
1.30
[1.05–1.60]
0.014 128.2
(184.1)
149.9
(196.5)
1.20
[0.98–1.48]
0.085 80.8 (110.4) 83.3
(158.6)
1.07
[0.87–1.32]
0.520
Median length of
stay, days (IQ range)
9.0 (6.0) 10.0 (7.0) 1.14
[1.03–1.26]
0.013 10.0 (9.0) 10.0 (9.0) 1.11
[1.00–1.23]
0.058 10.0 (9.0) 11.0
(8.0)
1.05
[0.95–1.17]
0.322
aTR (time ratios) and CR (cost ratios) correspond to ratios of the changes of outcomes between the two study periods in each hospital compared with the others, controlling for potential confounding fac-
tors (see text).
bThe numbers of patients treated with intravenous antibiotics during the pre- and post-intervention periods among the 200 patients included in the study for every hospital and every period were 102 and
114 in hospital A, 137 and 149 in hospital B, and 128 and 118 in hospital C, respectively.
cThe mean hospital acquisition costs per dose in year 2002 were used for every antibiotic prescribed during the two study periods.
dIncluding the cost of antibiotics, plus devices and nursing time (see text).
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periods. Independent variables in the final models included the
dummy-coded hospitals and study periods, and confounding factors
remaining after a backward selection from the following variables:
age, gender, Charlson comorbidity index, nosocomial infection, dif-
ficult-to-treat infection and difficult-to-treat pathogen, as defined in
Table 1. P values were two-tailed; P <_ 0.05 was considered to be
significant.
Results
The characteristics of the 1200 included patients are shown in
Table 1. Significant differences were found only for the pro-
portion of patients with no comorbidities which was higher in
hospital A in the pre-intervention period, and for the proportion
of patients suffering from nosocomial infections which was
higher in hospital C in the post-intervention period.
Inter-hospital differences were however present in the base-
line values of the measured outcomes. Hospital A (control) had
lower median values for the total duration of antibiotic treat-
ments (P < 0.001), costs of antibiotics (P = 0.003), global costs of
antimicrobial treatments (P < 0.001), and length of stay
(P = 0.003).
No decrease in the outcomes as defined in Table 2 was
observed in any of the participating hospitals. However, signifi-
cant increases were found only in hospital A (control) when
comparing it with the two other participating institutions while
adjusting for any potential changes in the patients’ character-
istics between the two study periods. Moreover, although the
differences were not statistically significant, the observed
increases in the parameters investigated were higher in hospital
B (low grade intervention) than in hospital C (high grade inter-
vention).
During the post-intervention period, 95/170 patients (56%) in
hospital B and 122/170 (72%) in hospital C were treated in
accordance to the guidelines (P = 0.002). Thirty patients in each
hospital were excluded because their indication to receive anti-
biotics was unclear or not included in the guidelines.
Discussion
In a previous study, Gums et al.7 attributed a decrease in the
length of patients’ stay to antibiotic control programmes includ-
ing consultations by multidisciplinary teams. In this study, the
implementation of practice guidelines by infectious disease con-
sultants, pharmacists, and in-house physicians, with or without
their reinforcement by a clinical pharmacist, was not associated
with any decrease in the duration of hospital antibiotic treat-
ments, their costs, or the length of patients’ stays. However,
a significant increase in the parameters investigated was
observed only in the control hospital, compared with the hospi-
tals which benefited from an intervention. Moreover, although
these differences were not statistically significant in the interven-
tion groups, the observed increases were higher in the hospital
with a low grade intervention than in the hospital with a high
grade intervention. The impact of the high grade intervention,
which included the reinforcement of the guidelines by a clinical
pharmacist, is demonstrated by a higher adherence to the guide-
lines (72%), compared with 56% in the hospital without
reinforcement or to published rates of 40–60%.8 These results
suggest a positive effect of the implementation of practice
guidelines for antibiotic use, particularly when they are
reinforced by a clinical pharmacist, thus arguing in favour of
multifaceted interventions and confirming the results of previous
studies that demonstrated the lack of efficacy of the distribution
guidelines, in the absence of additional measures.9
This study used a prospective, controlled, ‘before–after’
design. The same months were chosen for each observation
period to avoid seasonal biases. The different interventions were
randomly allocated to different hospitals to avoid contamination
biases. These institutions were similar in terms of size, activities,
and case-mix indexes, thus minimizing the risk of inappropriate
comparisons. In addition, the multivariable analyses took poten-
tial confounding factors into account, allowing us to estimate the
independent association of each of the interventions with the
measured outcomes.
Nevertheless, the control hospital had significantly lower
baseline durations of antibiotic treatments, costs and length of
stays than the others. In addition, although these parameters
increased significantly in this hospital between the two study
periods, they remained lower than in the others. As discussed by
Avorn & Solomon,10 many factors, other than the patients’
characteristics or their type of infection, may influence antibiotic
use. Such factors that may be cultural or economical, are diffi-
cult to capture in a study on antibiotic use and could have played
an unseen role in our results. Other limitations of this study
suggest caution while interpreting its results. First, outcomes
such as mortality, resistance rates to antibiotics or quality of
care were not assessed and may vary independently from the
costs, the duration of treatments or the length of stay. Second,
this study addressed only in-hospital antibiotic use and did not
include the treatments of patients transferred or discharged on
antibiotics. Third, it was not designed to determine the cost-
effectiveness of the implemented interventions.
In conclusion, this study illustrates the difficulties encoun-
tered when measuring the impact of interventions to promote the
rational use of antibiotics. Nevertheless, it suggests a positive
impact of the development and implementation of local guide-
lines, particularly when they are reinforced by a clinical
pharmacist.
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